DexCom, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000QTF8K1
DXCM
DexCom, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Medical Devices
NAME
DexCom, Inc.
ISIN
US2521311074
TICKER
DXCM
MIC
XNAS
REUTERS
DXCM.OQ
BLOOMBERG
DXCM US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 13.01.2025
DexCom
US2521311074
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. Internationa...
Tue, 07.01.2025
DexCom
US2521311074
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.
The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast.
Links to the webcast will be available on the Dexcom Investor Rela...
Sat, 21.12.2024
DexCom
US2521311074
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM).
On July 25, 2024, the Company announced its financial results for the second quarter of fiscal 2024, d...
Tue, 17.12.2024
DexCom
US2521311074
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association...
Tue, 17.12.2024
DexCom
US2521311074
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older.
This press relea...
Tue, 19.11.2024
DexCom
US2521311074
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combi...
Thu, 14.11.2024
DexCom
US2521311074
This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were f...
Thu, 24.10.2024
DexCom
US2521311074
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights:
Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis.
U.S. revenue declined 2% and international revenue grew 12% on a reported...
Mon, 21.10.2024
DexCom
US2521311074
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faru...
Fri, 18.10.2024
DexCom
US2521311074
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring syst...
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
